Fitch Affirms MSBAM 2013-C12
Berkshire's portfolio can give some guidance to weary investors.
The information and opinions presented herein are not meant to be taken as investment advice. We do our best to make sure the information presented in this article is factual and correct, but Zacks cannot be held responsible for any losses incurred from investment transactions made based on ...
Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.
Med-tech multinationals look to the East for growth in China.
In this second excerpt from their new book, Morningstar's Heather Brilliant and Elizabeth Collins detail how companies leverage cost advantage and switching costs to their benefit.
As the ultimate impact of Obamacare comes into focus, the sector’s winners and losers are becoming more apparent.
As the ultimate impact of Obamacare comes into focus, the sector's winners and losers are becoming more apparent.
Health-care exchanges provide the biggest uncertainty going into 2014.
Obamacare will benefit some sectors more than others, but poor economy and pricing pressures are the biggest challenges most health-care firms must face.